INTRODUCTION
Standard procedure for the assessment of axillary lymph nodes for more than 100 years was axillary lymph node dissection (ALND)-which involves dissection of 1 st , 2 nd and 3 rd levels of axilla, associated with significant morbidity including pain, numbness and tingling, seroma, infection, limited movements of the shoulder and lymphedema of the upper arm.
Thanks to the work of Morton et al. with melanoma of the skin, as well as the fact that the skin and breast tissue have common embryonic origin, there was the idea of applying a less invasive diagnostic methods for the assessment of tumor status of axilla-axillary sentinel lymph node biopsy (SLNB) (1) . By terminology, axillary sentinel lymph node is the first node that stands in the way of the lymphatic drainage of the primary tumor and that in a large percentage represents a tumor status of the remaining axillary lymph nodes basin.
About 85% of lymphatic drainage from any quadrant of the breast drains its lymph to axillary lymph nodes, so that axillary SLN with high precision represents the status of the remaining lymph nodes in the axilla (2) . Sentinel lymph node (one or more) should a) be the first lymph node in lymph drainage path from localization of the primary tumor to the regional lymph basin, b) that it can successfully be marked with a radioactive isotope Diagnostic Accuracy of Sentinel Lymph Node Biopsy in Axillary Lymph Nodes at the Early Stages of Breast Cancer or dye and c) that it can be successfully identified. Kreigh et al. (1993) were the first to present data on successful application of unfiltered Tc99 in breast cancer and identification of sentinel lymph nodes in 18 of 22 patients using a manual gamma probe that was followed by numerous other studies (Giliano et al., Albertini and al., Veronesi et al., Imoto et al., Motomura et al.) that used either dye or radioactive isotope labeling as a means for marking axillary SLN which had a percentage of identifying over 90% with the percentage of false-negative results below 10% (3). However, SLN biopsy is a relatively new method that has not yet been standardized and that requires clearly defined and precise collaboration between nuclear medicine specialists, pathologists and surgeon.
Therefore, all the authors in the beginning of application of SLN biopsy validate the results with complete axillary lymph node dissection (or axillary backup). Until now are made 69 clinical studies as well as five multicenter study in which the results of SLN biopsy were evaluated with ALND (4). According to estimates American Cancer Society in the 2011/2012 year, at the United States discovered 230480 new cases of invasive breast cancer with an additional 57650 women who had been diagnosed with breast cancer "in situ" (5) .
Although all present radiological techniques can define the parameter T and M parameter in patients with newly diagnosed breast cancer, their diagnostic value is unacceptably low and too expensive for the prediction of the parameter N in patients with negative clinical finding. Mammography "screening" procedure has resulted in the detection of breast cancer at early stage where the probability of the presence of axillary metastases is between 20-40% (T1a-c) and ALND is routinely carried out in these patients as part of the staging, regardless of clinically negative axilla (6) .
ALND is associated with a high incidence of early and late postoperative complications so that raises the question of justification for routine axillary lymph node dissection in all patients with breast cancer (7) . Detailed histological evaluation of 15 to 20 lymph nodes is practically impossible during standard pathological analysis. On other hand, focusing on only one or a few sentinel lymph nodes in the course of extensive histological analysis improves the accuracy of the histopathological axillary lymph nodes staging (8) . Randomized clinical trials have confirmed that avoiding axillary dissection in breast cancer with negative sentinel lymph nodes can maintain the current parameters for locoregional recurrence and overall survival, while reducing the percentage of postoperative morbidity (9, 10, 11) . Therefore, the radioactive guided biopsy of sentinel lymph node can be considered a new, minimally invasive standard axillary surgery in patients with early-stage breast cancer.
GOAL
The goal was to establish specificity, sensitivity, positive and negative predictive value of SNLB method in relation to the presence of malignant changes in axillary sentinel lymph node and to determine the actual need for implementation of ALND.
PATIENTS AND METHODS

Patients
The study included 50 female patients at the Clinic of Glandular and Oncological surgery CCU Sarajevo, with an initial breast cancer, aged 18-75 years in the period from January 2008 to January 2011, and which fulfilled the predefined criteria.
Methods
The study was of retrospective-prospective clinical manipulative and descriptive-analytical character. The sample consisted of patients who were admitted to the Clinic of Oncology and Glandular surgery with a diagnosis of breast cancer, at stage T1 and T2, which have been subjected to appropriate preoperative preparation. Preoperative injection of radio-active isotope Tc99 m albumin-nanocolloid was carried out at the Clinic of Nuclear Medicine CCUS, multiple, subcutaneous, above tumor at a dose of 0.2 ml, 640 mikroCi. 
RESULTS
The study included 50 patients who met criteria for inclusion in the study, the average age of the patient's was 51.32±10.5 years, with the youngest at age of 30 and the oldest at the age of 74 years. Analysis of tumor size showed that the patients had an average tumor size of 1.78±0.84 cm, with a 95% confidence interval (95% CI) of 1.482 to 2.079 cm.
Most tumors were larger than 1.5 cm in a total of 24 (48%). The largest recorded tumor size in the study was 4.0 <0.05 was accepted as statistically significant. The r presented in tables and charts.
The study included 50 patients who met criteria age of the patient's was 51.32±10.5 years, with the youn age of 74 years. Analysis of tumor size showed that the 1.78±0.84 cm, with a 95% confidence interval (95% CI) cm and the smallest 0.2 cm. Intraoperative identifi cation of SLN (one or more) by gamma probe was performed in all patients as a condition for inclusion of the patients into the study. Most of the patients had undergone qudrantectomy (n=21, 42%), and hemi mastectomy (n=14, 28%), mastectomy (n=7, 14%), and finally bisegmenctetomy (n=4, 8%) and segmentectomy (n=4, 8%).
Th e histopathological analysis revealed that the most common cancers were ductal (n=27, 54%, p=0.0184), and lobular (n=12, 24%) followed by other types (n=11, 22%). Under group of other group most cancer was of tubulo-lobular (n=4), and tubular (n=3) with one apocrine, mucinous, neuroendocrine and papillary (Table 1) . Table 2 . Lymph nodes analysis "TNM" (TNM Classifi cation of Malignant tumor) classifi cation showed that most patients with either with cancer in stage T1 (n=31, 62%, p= 0.0339), and somewhat less in stage T2 (n=11, 22%) and the least number at the stage Tcis (n=8, 16%). "AJCC" (American Joint Committee of Cancer) classification showed that most patients with any stage of cancer was in Ia stage (n=26, 52%, p=0.0661), in stage Ib (n=15, 30%) and in the stage 0 (n=5, 10%) with the least number in the stage IIa (n=4, 8%). Figure 2 shows that the average number of SLN in the total sample was approximately 2 (1.98±0.7) and ranged from 1-4. In patients with subsequent positive PH fi ndings the number of SLN was slightly higher and ranged from 2-3, as compared to those with negative PH fi ndings and ranged from [1] [2] [3] [4] .
Th e analysis of method sensitivity and specifi city was done based on the following data, positive or negative results of analysis of sentinel lymph nodes and on the basis of positive or negative fi ndings of axillary lymph nodes at the same patient. In 46 patients there was a negative result in sentinel lymph nodes as well as in the axillary lymph nodes and these fi ndings were classifi ed as true negative (TN), in two patients there was a positive fi nding in the sentinel lymph node and positive fi ndings in lymph node and these was classifi ed as a true positive (TP), in one patient there was a positive fi nding of sentinel lymph node while the axillary lymph node was negative so it is classifi ed as a false positive result (FP), and fi nally in one patient the sentinel lymph nodes were negative, while axillary lymph nodes were found positive so this fi nding is classifi ed as a false negative (FN) fi ndings. (Table 3) Based on the above analysis we obtained sensitivity of 67%, specificity 98%, PPV of 67%, NPV of 96% and diagnostic accuracy of 98%.
DISCUSSION
Th e hypothesis that one or more sentinel lymph node receives most lymphatic drainage from the primary breast tumor and axillary lymph node dissection can be avoided if the sentinel lymph node is negative is logical, intuitive and represents a new standard in the treatment of early-stage breast cancer.
However, SLN biopsy is a relatively new surgical technique that has its own learning curve, which is a highly multidisciplinary and which has not yet been standardized. Th e biggest dilemma regarding the use of SLN biopsy method is the impact on overall survival of patients and the percentage of local axillary recurrence compared to ALND. Results of several randomized controlled trials in clinically negative patients showed no diff erence in overall survival and local recurrence in patients who underwent SLNB method only and those patients who underwent simultaneous and SLNB and ALND (9, 10, 11, 12, 13) .
Diff erent types of radioactive colloids are used when performing SLN biopsy, diff erent particle carriers size. Using radio colloid particle size between 100 and 200 nm is a compromise between fast lymphatic drainage and optimum retention in the sentinel lymph node.
Th e percentage of sentinel lymph node identifi cation of 90-95% and the percentage of false-negative results of no more than 5-10% should be the target during the validation of the method (9, 14, 15) .
Th e average number of SLN per patient was two lymph nodes, while biopsy of more than 4 lymph nodes is not recommended due to the risk of developJoint Committee of Cancer) classification showed tha was in Ia stage (n=26, 52%, p=0.0661), in stage Ib (n= with the least number in the stage IIa (n=4, 8%). Figure 2 shows that the average number of SLN 2 (1.98±0.7) and ranged from 1-4. In patients with number of SLN was slightly higher and ranged from PH findings and ranged from 1-4. (9) .
After the "ex tempore" analysis (FS) is negative sentinel lymph node (or nodes) are routinely further examined by hematoxylin & eosin technique (H&E) as a control "ex tempore" analysis which is the standard practice of all involved in SLNB. If the H&E technique found negative nodes, remaining sentinel lymph node can be further analyzed by immuno-histochemical methods for cytokeratin (IHC), which is not yet standard practice of all centers that deal with the treatment of breast cancer.
Results of studies of PH SLN analysis shows that in about 10-20% of cases when IHC is used for cytokeratin are found micro metastases that are not registered in the examination of sentinel lymph nodes by H&E technique (16) .
In connection with the above is the issue of treatment of micro metastasis (<0.2 mm), their classifi cation and determination of appropriate stages of breast cancer and the impact on the recurrence and overall patient survival. Primary non-detected metastases are having prognostic and statistical signifi cance associated with 10-15 % of the deterioration in terms of overall survival (17).
In general, monitoring of patients after SLN biopsy was done during the whole life. Clinical studies have multiyear follow-up of patients after SLNB and showed that the percentage of overall survival and disease-free period was high (90.3 to 94.8% for overall survival and 81.5 to 87.6% for disease-free period) and was not signifi cantly diff erent compared to ALND (13, 15) 
CONCLUSION
Th e obtained values of sensitivity, specifi city, PPV, NPV, and accuracy of the this method are compatible and comparable with the results of the leading cancer centers that deal with breast cancer surgery and allow the introduction of SLN biopsy method in everyday surgical application at the Clinic of Oncology and glandular surgery CCU Sarajevo as a substitute for ALND in case of T1 and T2 stage breast cancer, with better co-ordination of multidisciplinary team of CCUS consisting of: surgeon, pathologist and nuclear medicine specialists.
